Solid Biosciences Inc (SLDB)

$9.08 -0.02 (-0.22%)
Market Cap 975.75M
Revenue (ttm) 0.00
Net Income (ttm) -174.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 536,200
Avg Vol 1,770,740
Day's Range N/A - N/A
Shares Out 107.23M
Stochastic %K 75%
Beta 2.41
Analysts Strong Sell
Price Target $17.50

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
BenKaitz
BenKaitz Aug. 17 at 3:22 PM
$SLDB
0 · Reply
chop14
chop14 Aug. 16 at 7:21 PM
$SLDB when FDA News is expected?
2 · Reply
pharmd2828
pharmd2828 Aug. 15 at 4:40 PM
$SLDB Over 34% of the entire company is owned by just three of the world's most sophisticated life science venture funds—RA Capital, Perceptive Advisors, and Bain Capital. These funds do not trade momentum; they hold structural control to capture the multi-billion-dollar market opportunity if SGT-003 secures FDA! Imho ! Plz do DD!
0 · Reply
pharmd2828
pharmd2828 Aug. 15 at 1:01 AM
$SLDB Today’s filings strengthen the investment thesis that sophisticated biotech investors see substantial value in SLDB and are positioning themselves for the next major catalyst. Imho ! plz do your DD! I’m long SLDB !
0 · Reply
pharmd2828
pharmd2828 Aug. 14 at 10:50 PM
$SLDB smart money is on board big time!
0 · Reply
chop14
chop14 Aug. 14 at 2:15 PM
$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY
0 · Reply
AnomalyDetective
AnomalyDetective Aug. 13 at 6:39 PM
💥 $RRGB still going strong on the MDA breakout signal from June 8th with earnings beat now up 62% from Week 26 selection and higher from MDA breakout signal. 💥 $SLDB off the highs from selection -- back in Segment 6 breakout signal still up +26.3% from Week 26 through the downturn. Credit: @vmbreakouts All new picks weekly picks for members out after the close: https://seekingalpha.com/mp/1201-value-momentum-breakouts Up to 12,600 daily picks per year released 2x per day on the automated website here: http://vmbreakouts.com
0 · Reply
chop14
chop14 Aug. 13 at 4:53 PM
$ARTL good. But volume still low $SLDB $PFE$JNJ $LLY
0 · Reply
vu_jade
vu_jade Aug. 11 at 1:45 AM
$SLDB great spot to get some
0 · Reply
Jusprag24
Jusprag24 Aug. 10 at 7:05 PM
$SLDB How nice would that be
1 · Reply
Latest News on SLDB
Solid Biosciences reports Q2 EPS (38c), consensus (47c)

2026-08-06T21:40:40.000Z - 12 days ago

Solid Biosciences reports Q2 EPS (38c), consensus (47c)

Solid Biosciences files automatic mixed securities shelf

2026-08-06T21:07:08.000Z - 12 days ago

Solid Biosciences files automatic mixed securities shelf

Solid Biosciences Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Solid Biosciences Quarterly report: Q2 2026

Solid Biosciences Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Solid Biosciences Earnings release: Q2 2026

Solid Biosciences Transcript: AGM 2026

Jun 10, 2026, 8:00 AM EDT - 2 months ago

Solid Biosciences Transcript: AGM 2026

Solid Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 4:00 PM EDT - 2 months ago

Solid Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:35 AM EDT - 2 months ago

Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright

2026-06-03T10:07:53.000Z - 2 months ago

Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2026, 4:05 PM EDT - 2 months ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at Upcoming Investor Conferences

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences price target lowered to $16 from $17 at Wedbush

2026-05-13T15:30:30.000Z - 3 months ago

Solid Biosciences price target lowered to $16 from $17 at Wedbush

Solid Biosciences price target raised to $18 from $17 at Piper Sandler

2026-05-13T11:12:14.000Z - 3 months ago

Solid Biosciences price target raised to $18 from $17 at Piper Sandler

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 12, 2026, 4:08 PM EDT - 3 months ago

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Solid Biosciences Quarterly report: Q1 2026

Solid Biosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Solid Biosciences Earnings release: Q1 2026

Solid Biosciences doses part participant in IMPACT DUCHENNE study

2026-05-07T18:40:55.000Z - 3 months ago

Solid Biosciences doses part participant in IMPACT DUCHENNE study

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

May 7, 2026, 8:00 AM EDT - 3 months ago

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences receives orphan drug designation for SGT-003 from EC

2026-04-28T13:07:07.000Z - 4 months ago

Solid Biosciences receives orphan drug designation for SGT-003 from EC

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Solid Biosciences Proxy statement: Proxy filing

Solid Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Solid Biosciences Proxy statement: Proxy filing

Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 2:15 PM EDT - 4 months ago

Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Solid Biosciences Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Solid Biosciences Proxy statement: Proxy filing

Solid Biosciences price target raised to $12 from $11 at JPMorgan

2026-03-25T11:05:12.000Z - 5 months ago

Solid Biosciences price target raised to $12 from $11 at JPMorgan

Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential

2026-03-20T11:20:59.000Z - 5 months ago

Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential

SRPT

Solid Biosciences initiated with a Buy at Guggenheim

2026-03-20T10:31:13.000Z - 5 months ago

Solid Biosciences initiated with a Buy at Guggenheim

Solid Biosciences files to sell 1.32M shares of common stock for holders

2026-03-19T21:11:46.000Z - 5 months ago

Solid Biosciences files to sell 1.32M shares of common stock for holders

Solid Biosciences files to sell 42.78M shares of common stock for holders

2026-03-19T21:10:19.000Z - 5 months ago

Solid Biosciences files to sell 42.78M shares of common stock for holders

Solid Biosciences reports Q4 EPS (53c), consensus (52c)

2026-03-19T20:25:28.000Z - 5 months ago

Solid Biosciences reports Q4 EPS (53c), consensus (52c)

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 19, 2026, 4:12 PM EDT - 5 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Registration statement: Registration filing

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Solid Biosciences Registration statement: Registration filing

Solid Biosciences Registration statement: Registration filing

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Solid Biosciences Registration statement: Registration filing

Solid Biosciences Earnings release: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Solid Biosciences Earnings release: Q4 2025

Solid Biosciences Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Solid Biosciences Annual report: Q4 2025

Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 11:30 AM EDT - 5 months ago

Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference

Solid Biosciences price target raised to $17 from $14 at Wedbush

2026-03-12T12:38:40.000Z - 5 months ago

Solid Biosciences price target raised to $17 from $14 at Wedbush

Solid Biosciences trading resumes

2026-03-11T17:30:14.000Z - 5 months ago

Solid Biosciences trading resumes

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

2026-03-11T17:10:35.000Z - 5 months ago

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

Mar 11, 2026, 1:01 PM EDT - 5 months ago

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

Solid Biosciences trading halted, news pending

2026-03-11T16:55:13.000Z - 5 months ago

Solid Biosciences trading halted, news pending

Solid Biosciences prices 14.97M shares at $5.61 in private placement

2026-03-06T13:44:49.000Z - 5 months ago

Solid Biosciences prices 14.97M shares at $5.61 in private placement

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Mar 6, 2026, 8:31 AM EST - 5 months ago

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 6, 2026, 8:30 AM EST - 5 months ago

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 10:30 AM EST - 6 months ago

Solid Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

Feb 9, 2026, 8:00 AM EST - 6 months ago

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 6, 2026, 8:00 AM EST - 6 months ago

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Solid Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 7 months ago

Solid Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 7 months ago

Solid Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Jan 13, 2026, 4:15 PM EST - 7 months ago

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Jan 12, 2026, 4:15 PM EST - 7 months ago

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Jan 12, 2026, 8:05 AM EST - 7 months ago

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 8 months ago

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Dec 16, 2025, 4:51 PM EST - 8 months ago

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Solid Biosciences Slides: Study presentation

Dec 12, 2025, 4:00 PM EST - 8 months ago

Solid Biosciences Slides: Study presentation

Solid Biosciences Slides: Company presentation

Dec 12, 2025, 2:00 PM EST - 8 months ago

Solid Biosciences Slides: Company presentation

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Dec 8, 2025, 8:00 AM EST - 9 months ago

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Solid Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 11:30 AM EST - 9 months ago

Solid Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Dec 1, 2025, 8:00 AM EST - 9 months ago

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Nov 17, 2025, 8:00 AM EST - 9 months ago

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Nov 6, 2025, 8:00 AM EST - 10 months ago

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Nov 3, 2025, 4:05 PM EST - 10 months ago

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Solid Biosciences Quarterly report: Q3 2025

Nov 3, 2025, 2:00 AM EST - 10 months ago

Solid Biosciences Quarterly report: Q3 2025

Solid Biosciences Earnings release: Q3 2025

Nov 3, 2025, 2:00 AM EST - 10 months ago

Solid Biosciences Earnings release: Q3 2025

Solid Biosciences Slides: Q3 2025

Nov 3, 2025, 2:00 AM EST - 10 months ago

Solid Biosciences Slides: Q3 2025

Solid Biosciences to Present at Upcoming Scientific Meetings

Oct 1, 2025, 8:00 AM EDT - 11 months ago

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Sep 25, 2025, 8:00 AM EDT - 11 months ago

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Sep 23, 2025, 8:00 AM EDT - 11 months ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Sep 23, 2025, 8:00 AM EDT - 11 months ago

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Solid Biosciences Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 3:10 PM EDT - 1 year ago

Solid Biosciences Transcript: Baird Global Healthcare Conference 2025

Solid Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:00 AM EDT - 1 year ago

Solid Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Solid Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:20 PM EDT - 1 year ago

Solid Biosciences Transcript: Cantor Global Healthcare Conference 2025

Solid Biosciences Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 1:45 PM EDT - 1 year ago

Solid Biosciences Transcript: Citi's Biopharma Back to School Conference

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 4:07 PM EDT - 1 year ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 2:30 AM EDT - 1 year ago

Solid Biosciences Quarterly report: Q2 2025

Solid Biosciences Earnings release: Q2 2025

Aug 12, 2025, 2:30 AM EDT - 1 year ago

Solid Biosciences Earnings release: Q2 2025

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 1 year ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 8, 2025, 4:05 PM EDT - 1 year ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 2:00 PM EDT - 1 year ago

Solid Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025, 4:06 PM EDT - 1 year ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Registration statement: Registration Filing

May 15, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Registration statement: Registration Filing

Solid Biosciences Quarterly report: Q1 2025

May 15, 2025, 3:00 AM EDT - 1 year ago

Solid Biosciences Quarterly report: Q1 2025

Solid Biosciences Earnings release: Q1 2025

May 15, 2025, 3:00 AM EDT - 1 year ago

Solid Biosciences Earnings release: Q1 2025

Solid Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 12:30 PM EDT - 1 year ago

Solid Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Proxy statement: Proxy Filing

Solid Biosciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Proxy statement: Proxy Filing

Solid Biosciences Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences Proxy statement: Proxy Filing

Solid Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 10, 2025, 2:15 PM EDT - 1 year ago

Solid Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Solid Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Solid Biosciences Transcript: Barclays 27th Annual Global Healthcare Conference

Solid Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 9:20 AM EDT - 1 year ago

Solid Biosciences Transcript: Leerink’s Global Healthcare Conference 2025

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 6, 2025, 4:16 PM EST - 1 year ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Solid Biosciences Registration statement: Registration Filing

Mar 6, 2025, 7:00 AM EST - 1 year ago

Solid Biosciences Registration statement: Registration Filing

Solid Biosciences Registration statement: Registration Filing

Mar 6, 2025, 7:00 AM EST - 1 year ago

Solid Biosciences Registration statement: Registration Filing

Solid Biosciences Annual report: Q4 2024

Mar 6, 2025, 1:30 AM EST - 1 year ago

Solid Biosciences Annual report: Q4 2024

Solid Biosciences Earnings release: Q4 2024

Mar 6, 2025, 1:30 AM EST - 1 year ago

Solid Biosciences Earnings release: Q4 2024

Solid Biosciences Transcript: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Transcript: Study Update

Solid Biosciences Press release: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Press release: Study Update

Solid Biosciences Slides: Study Update

Feb 18, 2025, 8:00 AM EST - 1 year ago

Solid Biosciences Slides: Study Update

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 1 year ago

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025, 6:45 AM EST - 1 year ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 21, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Solid Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Solid Biosciences Slides: FY 2025

Jan 15, 2025, 6:45 PM EST - 1 year ago

Solid Biosciences Slides: FY 2025

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 1 year ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Transcript: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Transcript: FDA Announcement

Solid Biosciences Press release: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Press release: FDA Announcement

Solid Biosciences Slides: FDA Announcement

Jan 8, 2025, 8:30 AM EST - 1 year ago

Solid Biosciences Slides: FDA Announcement

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 1 year ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 9:30 AM EST - 1 year ago

Solid Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Solid Biosciences Transcript: Citi's 2024 Global Healthcare Conference

Dec 4, 2024, 1:00 PM EST - 1 year ago

Solid Biosciences Transcript: Citi's 2024 Global Healthcare Conference

Solid Biosciences Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 8:30 AM EST - 1 year ago

Solid Biosciences Transcript: Jefferies London Healthcare Conference 2024

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Earnings release: Q3 2024

Nov 6, 2024, 1:30 AM EST - 1 year ago

Solid Biosciences Earnings release: Q3 2024

Solid Biosciences Quarterly report: Q3 2024

Nov 6, 2024, 1:30 AM EST - 1 year ago

Solid Biosciences Quarterly report: Q3 2024

Solid Biosciences Transcript: Chardan's 8th Annual Genetic Medicines Conference

Sep 30, 2024, 11:00 AM EDT - 2 years ago

Solid Biosciences Transcript: Chardan's 8th Annual Genetic Medicines Conference

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 9:30 AM EDT - 2 years ago

Solid Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 2 years ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Quarterly report: Q2 2024

Aug 12, 2024, 2:30 AM EDT - 2 years ago

Solid Biosciences Quarterly report: Q2 2024

Solid Biosciences Earnings release: Q2 2024

Aug 12, 2024, 2:30 AM EDT - 2 years ago

Solid Biosciences Earnings release: Q2 2024

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 2 years ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Registration statement: Registration Filing

May 15, 2024, 8:00 AM EDT - 2 years ago

Solid Biosciences Registration statement: Registration Filing

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15, 2024, 7:52 AM EDT - 2 years ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

BenKaitz
BenKaitz Aug. 17 at 3:22 PM
$SLDB
0 · Reply
chop14
chop14 Aug. 16 at 7:21 PM
$SLDB when FDA News is expected?
2 · Reply
pharmd2828
pharmd2828 Aug. 15 at 4:40 PM
$SLDB Over 34% of the entire company is owned by just three of the world's most sophisticated life science venture funds—RA Capital, Perceptive Advisors, and Bain Capital. These funds do not trade momentum; they hold structural control to capture the multi-billion-dollar market opportunity if SGT-003 secures FDA! Imho ! Plz do DD!
0 · Reply
pharmd2828
pharmd2828 Aug. 15 at 1:01 AM
$SLDB Today’s filings strengthen the investment thesis that sophisticated biotech investors see substantial value in SLDB and are positioning themselves for the next major catalyst. Imho ! plz do your DD! I’m long SLDB !
0 · Reply
pharmd2828
pharmd2828 Aug. 14 at 10:50 PM
$SLDB smart money is on board big time!
0 · Reply
chop14
chop14 Aug. 14 at 2:15 PM
$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY
0 · Reply
AnomalyDetective
AnomalyDetective Aug. 13 at 6:39 PM
💥 $RRGB still going strong on the MDA breakout signal from June 8th with earnings beat now up 62% from Week 26 selection and higher from MDA breakout signal. 💥 $SLDB off the highs from selection -- back in Segment 6 breakout signal still up +26.3% from Week 26 through the downturn. Credit: @vmbreakouts All new picks weekly picks for members out after the close: https://seekingalpha.com/mp/1201-value-momentum-breakouts Up to 12,600 daily picks per year released 2x per day on the automated website here: http://vmbreakouts.com
0 · Reply
chop14
chop14 Aug. 13 at 4:53 PM
$ARTL good. But volume still low $SLDB $PFE$JNJ $LLY
0 · Reply
vu_jade
vu_jade Aug. 11 at 1:45 AM
$SLDB great spot to get some
0 · Reply
Jusprag24
Jusprag24 Aug. 10 at 7:05 PM
$SLDB How nice would that be
1 · Reply
garygb
garygb Aug. 8 at 10:37 PM
$SLDB Smart money likes this so I'm adding, again.
0 · Reply
chop14
chop14 Aug. 8 at 9:52 AM
$ARTL no rs this year maybe more atm (dilution) 😮 $JNJ $PFE $SLDB
1 · Reply
dcrown
dcrown Aug. 7 at 2:36 PM
$SLDB stop the selling , geez
0 · Reply
pharmd2828
pharmd2828 Aug. 6 at 10:30 PM
$SLDB Setting up an S-3 prospectus supplement acts like a credit line. The company does not have to sell $200 million worth of stock immediately. Instead, they can sell small amounts over time (an At-The-Market program) whenever their stock price surges on good news.imho
1 · Reply
focafoca99
focafoca99 Aug. 6 at 9:49 PM
$SLDB selling up to $200 million of common stock via a new prospectus supplement under its S-3 shelf registration.
2 · Reply
pharmd2828
pharmd2828 Aug. 6 at 6:36 PM
$SLDB whales of Wall Street keeps on adding!
0 · Reply
kellymone2
kellymone2 Aug. 5 at 6:36 AM
$SLDB no one is talking about this amazing stock
2 · Reply
pharmd2828
pharmd2828 Aug. 2 at 6:50 PM
$SLDB comparing “smart-money signal”: RGNX * BlackRock 🟢 * Redmile 🟢🟢🟢 * JPMorgan 🟢 * State Street 🟢 * Vanguard 🟢 * Morgan Stanley 🟢 * Goldman 🟢 SLDB * RA Capital 🟢🟢🟢🟢🟢 * Perceptive 🟢🟢🟢🟢🟢 * Bain Capital Life Sciences 🟢🟢🟢🟢🟢 * Invus 🟢🟢🟢🟢 * Deep Track 🟢🟢🟢🟢 * Vestal Point 🟢🟢🟢🟢 SLDB stands out ! Very sophisticated healthcare investors are involved!
0 · Reply
pharmd2828
pharmd2828 Aug. 2 at 4:44 PM
$SLDB SGT-003 → precisions DMD gene therapy → pediatric population → 6-month-old dosing → strong biological mechanism → microdystrophin expression → DAPC restoration → biomarker improvements → favorable safety so far → Phase 3 underway → FDA discussions → $240M institutional financing → EU orphan designation → EMA pediatric alignment → potential AA strategy
0 · Reply
pharmd2828
pharmd2828 Aug. 1 at 9:14 PM
$SLDB If Solid proves SGT-003 is safe and effective in infants (ages 0–3), they unlock an unserved patient population where no other gene therapy operates. Then a mega blockbuster gene therapy will be born to thrive!imho
0 · Reply
Jonrenie
Jonrenie Jul. 31 at 2:22 PM
$SLDB more, more, more. How do you like it?
0 · Reply
pharmd2828
pharmd2828 Jul. 31 at 10:57 AM
$SLDB For SLDB, BlackRock crossing the 5% threshold is a structural win. It improves overall stock liquidity, reduces the free float available for short-sellers or retail churn, and confirms that SLDB is increasingly embedded in major sector index funds. Imho plz do your DD!
0 · Reply